Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy
- 7 October 2004
- journal article
- other
- Published by Springer Nature in Leukemia
- Vol. 18 (12) , 2044-2046
- https://doi.org/10.1038/sj.leu.2403533
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone(T-VAD doxil): a phase II multicenter studyAnnals of Oncology, 2004
- Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatmentJournal of Thrombosis and Haemostasis, 2003
- Thalidomide in multiple myeloma: current status and future prospectsBritish Journal of Haematology, 2002
- Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapyBlood, 2002
- Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapyBlood, 2001
- Deep Venous Thrombosis and Thalidomide Therapy for Multiple MyelomaNew England Journal of Medicine, 2001
- Total Therapy With Tandem Transplants for Newly Diagnosed Multiple MyelomaBlood, 1999